By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today announced the New York State Department of Health has approved its ColoVantage colorectal cancer test for use in the state, making it available in all 50 states.

Quest added that it believes ColoVantage is the first molecular colorectal cancer detection method employing venal blood specimen to be approved by the state.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.